35 results
Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years

Thumbnail

D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center

Thumbnail

D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria

Thumbnail

D3.373 - Hives and hidden codes: detection of miRNA in chronic spontaneous urticaria patients - pilot study

Thumbnail

D3.369 - Childhood exhaled nitric oxide levels predict new-onset allergic rhinitis in adolescence and young adulthood

Thumbnail

D3.370 - Inverse Association between Mitochondrial DNA Copy Number and Atopic Dermatitis in Schoolchildren

Thumbnail

D3.371 - Impact of sensitization to main allergen molecules during childhood on adult asthma, atopic dermatitis, rhinitis and food allergy in the BAMSE cohort

Thumbnail

D3.372 - SLC27A2 marks lipid peroxidation in nasal epithelial cells driven by type 2 inflammation in chronic rhinosinusitis with nasal polyps

Thumbnail

D3.374 - Assessment of leukotriene E4 as a long term marker of inflammation between regular maintenance (36 weeks therapy) versus as-needed intranasal corticosteroid use in pediatric allergic rhinitis

Thumbnail

D3.375 - The impact of strontium exposure on allergic rhinitis development via IRE1-mediated protein expression: ECHO-COCOA study

Thumbnail

D3.376 - The severity of the dyspnea and symptom components of COPD determines the disease course

Thumbnail

D3.377 - Eosinophil-derived neurotoxin measured in nasal mucosal lining fluid (Nasosorption) is a promising type 2 biomarker in allergic rhinitis

Thumbnail

D3.378 - Long Covid in epithelial barrier type2 disease: an Italian experience